

Cardiotoxicity of anticancer treatments: Epidemiology,

Ca-A Cancer Journal for Clinicians

66, 309-325

DOI: [10.3322/caac.21341](https://doi.org/10.3322/caac.21341)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cancer treatment-related cardiac toxicity: prevention, assessment and management. Medical Oncology, 2016, 33, 84.	2.5	27
2	Biomarkers and Cancer Therapy-Related Cardiac Dysfunction. Current Cardiovascular Risk Reports, 2016, 10, 1.	2.0	0
4	The Challenge of Radiation-Induced Restrictive Cardiomyopathy and Outcomes After Heart Transplantation. Journal of Cardiac Failure, 2016, 22, 479-480.	1.7	4
5	Chemotherapy-induced cardiotoxicity: importance of early detection. Expert Review of Cardiovascular Therapy, 2016, 14, 1297-1299.	1.5	16
6	ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 400-402.	7.3	29
8	Cucurbitacin-I induces hypertrophy in H9c2 cardiomyoblasts through activation of autophagy via MEK/ERK1/2 signaling pathway. Toxicology Letters, 2016, 264, 87-98.	0.8	29
9	Pathophysiology of exercise intolerance in breast cancer survivors with preserved left ventricular ejection fraction. Clinical Science, 2016, 130, 2239-2244.	4.3	24
10	EXercise to prevent Anthracycline-based Cardio-Toxicity (EXACT) in individuals with breast or hematological cancers: a feasibility study protocol. Pilot and Feasibility Studies, 2016, 2, 44.	1.2	11
11	Extended anti-HER2 therapy in early breast cancer: longer beats shorter?. Current Opinion in Oncology, 2016, 28, 469-475.	2.4	4
13	Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy. Expert Review of Molecular Diagnostics, 2017, 17, 245-256.	3.1	66
14	Cardio-Onco-Hematología en la práctica clínica. Documento de consenso y recomendaciones. Revista Española De Cardiología, 2017, 70, 474-486.	1.2	72
15	Emerging Cardiac Imaging Modalities for the Early Detection of Cardiotoxicity Due to Anticancer Therapies. Revista Española De Cardiología (English Ed), 2017, 70, 487-495.	0.6	16
16	Cardiac Fibrosis and Arrhythmogenesis. , 2017, 7, 1009-1049.		97
17	Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Japanese Journal of Clinical Oncology, 2017, 47, 678-682.	1.3	34
18	Cardio-oncology: What is the Best Practice we can all strive for?. International Journal of Cardiology, 2017, 241, 393-394.	1.7	5
19	Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey. International Journal of Cardiology, 2017, 241, 387-392.	1.7	27
20	Rationale for Cardio-Oncology Units. Revista Española De Cardiología (English Ed), 2017, 70, 583-589.	0.6	4
21	Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations. Revista Española De Cardiología (English Ed), 2017, 70, 474-486.	0.6	54

#	ARTICLE	IF	CITATIONS
22	Early Diagnosis and Prediction of Anticancer Drug-induced Cardiotoxicity: From Cardiac Imaging to Omics Technologies. Revista Espanola De Cardiologia (English Ed), 2017, 70, 576-582.	0.6	5
23	Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy. Npj Precision Oncology, 2017, 1, 31.	5.4	102
24	Elucidation of protective efficacy of Pentahydroxy flavone isolated from Madhuca indica against arsenite-induced cardiomyopathy: Role of Nrf-2, PPAR- γ , c-fos and c-jun. Environmental Toxicology and Pharmacology, 2017, 56, 172-185.	4.0	25
25	Nuevas técnicas de imagen cardiaca en la detección precoz de cardiotoxicidad secundaria a tratamientos oncológicos. Revista Espanola De Cardiologia, 2017, 70, 487-495.	1.2	29
26	Diagnóstico y prevención de la cardiotoxicidad inducida por fármacos antineoplásicos: de la imagen a las tecnologías «ómicas». Revista Espanola De Cardiologia, 2017, 70, 576-582.	1.2	11
27	Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts. Current Oncology Reports, 2017, 19, 55.	4.0	18
29	Lung cancer as a cardiotoxic state: a review. Medical Oncology, 2017, 34, 159.	2.5	12
30	Improving Provision of Care for Long-term Survivors of Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e1-e9.	0.4	17
31	Noninvasive Cardiac Radiation for Ablation of Ventricular Tachycardia. New England Journal of Medicine, 2017, 377, 2325-2336.	27.0	462
32	Rehabilitation of Cancer Survivors with Long-Term Toxicities. Oncology Research and Treatment, 2017, 40, 764-771.	1.2	25
33	The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy. Advances in Experimental Medicine and Biology, 2017, 1000, 103-129.	1.6	19
34	MicroRNA therapy inhibits hepatoblastoma growth in vivo by targeting β -catenin and Wnt signaling. Hepatology Communications, 2017, 1, 168-183.	4.3	51
35	Cardiovascular disease and physical activity in adult cancer survivors: a nested, retrospective study from the Atlantic PATH cohort. Journal of Cancer Survivorship, 2017, 11, 264-273.	2.9	23
36	Oncology Drug Therapy: Cardiotoxicity and the Discipline of Cardio-oncology. , 2017, , 201-221.		1
37	Evaluation and Long-Term Outcomes of Cardiac Toxicity in Paediatric Cancer Patients. , 0, ,		0
38	Antioxidant Therapeutic Strategies for Cardiovascular Conditions Associated with Oxidative Stress. Nutrients, 2017, 9, 966.	4.1	129
39	Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study. BMC Pharmacology & Toxicology, 2017, 18, 75.	2.4	13
41	Coordinating Cardio-Oncology Care. , 2017, , 221-236.		0

#	ARTICLE	IF	CITATIONS
42	Standing up to the cardiometabolic consequences of hematological cancers. Blood Reviews, 2018, 32, 349-360.	5.7	5
43	Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy. ESC Heart Failure, 2018, 5, 620-629.	3.1	57
44	Cardioprotection in the Modern Era of Cancer Chemotherapy. Cardiology in Review, 2018, 26, 113-121.	1.4	9
45	Arginine: Challenges and opportunities of this two-faced molecule in cancer therapy. Biomedicine and Pharmacotherapy, 2018, 102, 594-601.	5.6	42
47	Cell Density-Dependent Cytological Stage Profile and Its Application for a Screen of Cytostatic Agents Active Toward Leukemic Stem Cells. Stem Cells and Development, 2018, 27, 488-513.	2.1	5
48	Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation, 2018, 137, e30-e66.	1.6	500
49	Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention. Annual Review of Medicine, 2018, 69, 97-111.	12.2	31
50	Chemotherapy-Related Cardiac Dysfunction. Circulation Genomic and Precision Medicine, 2018, 11, e001753.	3.6	64
51	Does Cancer Affect Cardiac Function Prior to Cancer Therapy Exposure?. Canadian Journal of Cardiology, 2018, 34, 234-235.	1.7	2
52	Changes in the prevalence of comorbidity in the Australian population with cancer, 2007-2014. Cancer Epidemiology, 2018, 54, 56-62.	1.9	11
53	Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-oneAtrial. European Journal of Cancer, 2018, 94, 126-137.	2.8	163
54	Comorbidity, physical and mental health among cancer patients and survivors: An Australian population-based study. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e181-e192.	1.1	56
55	Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. Medicinal Research Reviews, 2018, 38, 325-376.	10.5	50
56	Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC). Clinical and Translational Oncology, 2018, 20, 687-694.	2.4	12
57	Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience. European Journal of Heart Failure, 2018, 20, 898-906.	7.1	54
58	Preventing Today's Survivors of Breast Cancer From Becoming Tomorrow's Cardiac Patients. Journal of Oncology Practice, 2018, 14, 213-214.	2.5	1
59	The breast cancer patient in the cardioncology unit. Journal of Thoracic Disease, 2018, 10, S4306-S4322.	1.4	12
60	Cardiovascular disease in survivors of childhood cancer. Current Opinion in Pediatrics, 2018, 30, 628-638.	2.0	43

#	ARTICLE	IF	CITATIONS
61	Emergence, Development, and Future of Cardio-Oncology in China. Chinese Medical Journal, 2018, 131, 2640-2644.	2.3	5
62	Cancer and the Broken Heart. Journal of Infusion Nursing, 2018, 41, 229-240.	2.3	6
63	Updates in Anthracycline-Mediated Cardiotoxicity. Frontiers in Pharmacology, 2018, 9, 1262.	3.5	133
64	Bioinformatics identification of potential candidate blood indicators for doxorubicin-induced heart failure. Experimental and Therapeutic Medicine, 2018, 16, 2534-2544.	1.8	6
65	Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy: A narrative review. Biomedicine and Pharmacotherapy, 2018, 107, 989-996.	5.6	38
66	Beneficial role of virgin coconut oil supplementation against acute methotrexate chemotherapy-induced oxidative toxicity and inflammation in rats. Integrative Medicine Research, 2018, 7, 257-263.	1.8	26
67	A proteome-wide systems toxicological approach deciphers the interaction network of chemotherapeutic drugs in the cardiovascular milieu. RSC Advances, 2018, 8, 20211-20221.	3.6	4
68	Safety concerns regarding ablative radiotherapy for ventricular tachycardia. Radiotherapy and Oncology, 2018, 128, 387.	0.6	3
69	Protective Mechanism of Hydrogen Sulfide against Chemotherapy-Induced Cardiotoxicity. Frontiers in Pharmacology, 2018, 9, 32.	3.5	11
70	Atherogenic coefficient and atherogenic index in Doxorubicin-induced cardiotoxicity: impact of date palm extract. Comparative Clinical Pathology, 2018, 27, 1515-1522.	0.7	3
71	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Heart Lung and Circulation, 2018, 27, 1123-1208.	0.4	262
72	Cardiotoxicity. , 2018, , 367-406.		4
73	Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detectionâ€”The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress. International Journal of Molecular Sciences, 2018, 19, 797.	4.1	14
74	Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial. Pediatric Blood and Cancer, 2018, 65, e27308.	1.5	39
75	Les cardiomyopathies toxiques li��es aux chimioth��rapies. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2018, 2018, 10-14.	0.0	0
76	Light-Activatable Assembled Nanoparticles to Improve Tumor Penetration and Eradicate Metastasis in Triple Negative Breast Cancer. Advanced Functional Materials, 2018, 28, 1801738.	14.9	37
77	Pregnancy Among Survivors of Childhood Cancer: Cardiovascular Considerations. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 54.	0.9	5
78	Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology. Heart Failure Reviews, 2019, 24, 91-100.	3.9	47

#	ARTICLE	IF	CITATIONS
79	Hypertension: a new treatment for an old disease? Targeting the immune system. British Journal of Pharmacology, 2019, 176, 2028-2048.	5.4	20
80	Calcitriol Attenuates Doxorubicin-Induced Cardiac Dysfunction and Inhibits Endothelial-to-Mesenchymal Transition in Mice. Cells, 2019, 8, 865.	4.1	27
81	Understanding Long-Term Cancer Survivorsâ€™ Preferences for Ongoing Medical Care. Journal of General Internal Medicine, 2019, 34, 2091-2097.	2.6	23
82	Low doses of ionizing radiation activate endothelial cells and induce angiogenesis in peritumoral tissues. Radiotherapy and Oncology, 2019, 141, 256-261.	0.6	11
83	Takotsubo cardiomyopathy in cancer patients. Cardio-Oncology, 2019, 5, 7.	1.7	34
84	Nanocatalytic Medicine. Advanced Materials, 2019, 31, e1901778.	21.0	396
85	Antineoplastic-related cardiovascular toxicity: A systematic review and meta-analysis in Asia. Critical Reviews in Oncology/Hematology, 2019, 141, 95-101.	4.4	4
86	Mesenchymal Stem Cell Therapy for Doxorubicin-Induced Cardiomyopathy: Potential Mechanisms, Governing Factors, and Implications of the Heart Stem Cell Debate. Frontiers in Pharmacology, 2019, 10, 635.	3.5	29
87	Hypertension in the Cardio-Oncology Clinic. Heart Failure Clinics, 2019, 15, 487-495.	2.1	16
88	Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms. Frontiers in Pharmacology, 2019, 10, 884.	3.5	20
89	Co-culturing with hypoxia pre-conditioned mesenchymal stem cells as a new strategy for the prevention of irradiation-induced fibroblast-to-myofibroblast transition. Oncology Reports, 2019, 42, 1781-1792.	2.6	7
90	Chemotherapy, cardiovascular disease and precision medicine: Toward truly individualized treatment for precision cardio-oncology?. International Journal of Cardiology, 2019, 280, 198-199.	1.7	1
91	SEOM clinical guidelines on cardiovascular toxicity (2018). Clinical and Translational Oncology, 2019, 21, 94-105.	2.4	20
92	Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients. Cancer Chemotherapy and Pharmacology, 2019, 84, 599-607.	2.3	16
93	Cardiotoxicities of Modern Treatments in Breast Cancer. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 34.	0.9	2
94	Challenges in Cardiovascular Risk Prediction and Stratification in Women. Cardiovascular Innovations and Applications, 2019, 3, .	0.3	2
95	A size-tunable and multi-responsive nanoplatform for deep tumor penetration and targeted combinatorial radio-/chemotherapy. Journal of Materials Chemistry B, 2019, 7, 4484-4498.	5.8	17
96	Trends in the prevalence of malignancy among patients admitted with acute heart failure and associated outcomes: a nationwide population-based study. Heart Failure Reviews, 2019, 24, 989-995.	3.9	9

#	ARTICLE	IF	CITATIONS
97	Cardiomyopathy in Children: Classification and Diagnosis: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 140, e9-e68.	1.6	186
98	A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 163-173.	2.3	10
99	Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer – A real-world data-based, nationwide classification analysis. <i>International Journal of Cardiology</i> , 2019, 285, 47-52.	1.7	25
100	Noncancer mortality among adolescents and young adults with cancer. <i>Cancer</i> , 2019, 125, 2107-2114.	4.1	40
101	Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children’s Oncology Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 12-21.	1.6	66
102	Reactive Oxygen Species (ROS)-Based Nanomedicine. <i>Chemical Reviews</i> , 2019, 119, 4881-4985.	47.7	1,519
103	Oncologic therapies associated with cardiac toxicities: how to minimize the risks. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 359-374.	2.4	4
104	Yoga for symptom management in oncology: A review of the evidence base and future directions for research. <i>Cancer</i> , 2019, 125, 1979-1989.	4.1	93
105	Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity. <i>Breast Journal</i> , 2019, 25, 444-449.	1.0	6
106	Omentin protects H9c2 cells against docetaxel cardiotoxicity. <i>PLoS ONE</i> , 2019, 14, e0212782.	2.5	16
107	Bragatston study protocol: a multicentre cohort study on automated quantification of cardiovascular calcifications on radiotherapy planning CT scans for cardiovascular risk prediction in patients with breast cancer. <i>BMJ Open</i> , 2019, 9, e028752.	1.9	16
108	<p>Preparation Of Nanobubbles Modified With A Small-Molecule CXCR4 Antagonist For Targeted Drug Delivery To Tumors And Enhanced Ultrasound Molecular Imaging</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 9139-9157.	6.7	17
109	An international survey of healthcare providers’ knowledge of cardiac complications of cancer treatments. <i>Cardio-Oncology</i> , 2019, 5, 12.	1.7	24
110	Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. <i>Oncologist</i> , 2019, 24, e1034-e1043.	3.7	13
111	Antitumor profiles and cardiac electrophysiological effects of aurora kinase inhibitor ZM447439. <i>Korean Journal of Physiology and Pharmacology</i> , 2019, 23, 393.	1.2	2
112	Cardio-oncological management of patients. <i>Seminars in Oncology</i> , 2019, 46, 408-413.	2.2	10
113	Feasibility and Outcomes of an Exercise Intervention for Chemotherapy-Induced Heart Failure. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2019, 39, 199-203.	2.1	8
114	Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable. <i>Medicine and Science in Sports and Exercise</i> , 2019, 51, 2375-2390.	0.4	1,443

#	ARTICLE	IF	CITATIONS
115	Antioxidant potential of garlic oil supplementation prevents cyclophosphamide-induced oxidative testicular damage and endocrine depletion in rats. <i>Journal of Nutrition & Intermediary Metabolism</i> , 2019, 18, 100109.	1.7	20
116	Roles of pharmacogenomics in non-anthracycline antineoplastic-induced cardiovascular toxicities: A systematic review and meta-analysis of genotypes effect. <i>International Journal of Cardiology</i> , 2019, 280, 190-197.	1.7	10
117	Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. <i>Clinical Breast Cancer</i> , 2019, 19, e306-e318.	2.4	16
118	L-arginine/5-fluorouracil combination treatment approaches cells selectively: Rescuing endothelial cells while killing MDA-MB-468 breast cancer cells. <i>Food and Chemical Toxicology</i> , 2019, 123, 399-411.	3.6	17
119	Phase I/II Trial of Electrophysiology-Guided Noninvasive Cardiac Radioablation for Ventricular Tachycardia. <i>Circulation</i> , 2019, 139, 313-321.	1.6	288
120	Breast Cancer and Heart Failure. <i>Heart Failure Clinics</i> , 2019, 15, 65-75.	2.1	10
121	Equitably improving outcomes for cancer survivors and supporting caregivers: A blueprint for care delivery, research, education, and policy. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 35-49.	329.8	124
122	Cardiovascular and other competing causes of death among patients with cancer from 2006 to 2015: An Australian population-based study. <i>Cancer</i> , 2019, 125, 442-452.	4.1	30
123	Cardiovascular Effects of Cancer Therapy. , 2020, , 649-664.e4.		1
124	Fully automated and comprehensive MRI-based left-ventricular contractility analysis in post-chemotherapy breast cancer patients. <i>British Journal of Radiology</i> , 2020, 93, 20190289.	2.2	5
125	Cardiovascular Magnetic Resonance Imaging. <i>Journal of Thoracic Imaging</i> , 2020, 35, 12-25.	1.5	8
126	Chemoprotective role of an extract of the heart of the Phoenix dactylifera tree on adriamycin-induced cardiotoxicity and nephrotoxicity by regulating apoptosis, oxidative stress and PD-1 suppression. <i>Food and Chemical Toxicology</i> , 2020, 135, 111045.	3.6	20
128	Noninvasive Radioablation of Ventricular Tachycardia. <i>Cardiology in Review</i> , 2020, 28, 283-290.	1.4	0
129	Vascular Endothelial Growth Factor (VEGF) Inhibitor Cardiotoxicity: What Should We Know?. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.9	0
130	Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e018143.	3.7	23
131	Healthcare utilization and hospital variation in cardiac surveillance during breast cancer treatment: a nationwide prospective study in 5000 Dutch breast cancer patients. <i>Cardio-Oncology</i> , 2020, 6, 14.	1.7	6
132	Metabolic Changes Precede Radiation-Induced Cardiac Remodeling in Beagles: Using Noninvasive ¹⁸ F-FDG (¹⁸ F-Fludeoxyglucose) and ¹³ N-Ammonia Positron Emission Tomography/Computed Tomography Scans. <i>Journal of the American Heart Association</i> , 2020, 9, e016875.	3.7	11
133	Quantification of Myocardial Dosimetry and Glucose Metabolism Using a 17-Segment Model of the Left Ventricle in Esophageal Cancer Patients Receiving Radiotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 1599.	2.8	3

#	ARTICLE	IF	CITATIONS
134	Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 733-741.	2.5	6
135	Cardiovascular disease, risk factors, and health behaviors among cancer survivors and spouses: A MEPS Study. <i>Cancer Medicine</i> , 2020, 9, 6864-6874.	2.8	6
136	Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2. <i>Frontiers in Oncology</i> , 2020, 10, 1555.	2.8	5
137	Cardiotoxicity of Novel Targeted Hematological Therapies. <i>Life</i> , 2020, 10, 344.	2.4	20
138	The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population-based study. <i>EJHaem</i> , 2020, 1, 489-497.	1.0	5
139	Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients from Southern Sri Lanka: An Echocardiographic Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-8.	1.9	9
140	Electrocardiographic characteristics of diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy. <i>Journal of Electrocardiology</i> , 2020, 60, 195-199.	0.9	9
141	A Comparative Study of Rat Urine ¹ H-NMR Metabolome Changes Presumably Arising from Isoproterenol-Induced Heart Necrosis Versus Clarithromycin-Induced QT Interval Prolongation. <i>Biology</i> , 2020, 9, 98.	2.8	1
142	Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative. <i>Oncologist</i> , 2020, 25, 712-721.	3.7	2
143	Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin. <i>Journal of Clinical Medicine</i> , 2020, 9, 1418.	2.4	27
144	The Role of Antioxidants in Ameliorating Cyclophosphamide-Induced Cardiotoxicity. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-14.	4.0	37
145	Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues. <i>Current Oncology Reports</i> , 2020, 22, 67.	4.0	20
146	Tumor-Specific Chemotherapy by Nanomedicine-Enabled Differential Stress Sensitization. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 9693-9701.	13.8	85
147	Activation of the <sc>MET</sc> receptor attenuates doxorubicin-induced cardiotoxicity in vivo and in vitro. <i>British Journal of Pharmacology</i> , 2020, 177, 3107-3122.	5.4	20
148	Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. <i>Cancers</i> , 2020, 12, 617.	3.7	4
149	Tumor-Specific Chemotherapy by Nanomedicine-Enabled Differential Stress Sensitization. <i>Angewandte Chemie</i> , 2020, 132, 9780-9788.	2.0	13
150	Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2-mediated activation of forkhead box O1. <i>Journal of Biological Chemistry</i> , 2020, 295, 4265-4276.	3.4	40
151	Temporal Trends in the Prevalence of Cancer and Its Impact on Outcome in Patients With First Myocardial Infarction: A Nationwide Study. <i>Journal of the American Heart Association</i> , 2020, 9, e014383.	3.7	26

#	ARTICLE	IF	CITATIONS
152	Environmentally responsive hydrogels for repair of cardiovascular tissue. <i>Heart Failure Reviews</i> , 2021, 26, 1273-1285.	3.9	13
153	Inhibition of cardiomyocyte differentiation of human induced pluripotent stem cells by Ribavirin: Implication for its cardiac developmental toxicity. <i>Toxicology</i> , 2020, 435, 152422.	4.2	19
154	Nexus of Cancer and Cardiovascular Disease for Australia's First Peoples. <i>JCO Global Oncology</i> , 2020, 6, 115-119.	1.8	6
155	Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. <i>Annals of Oncology</i> , 2020, 31, 171-190.	1.2	582
156	The characteristics and regularities of cardiac adverse drug reactions induced by Chinese materia medica: A bibliometric research and association rules analysis. <i>Journal of Ethnopharmacology</i> , 2020, 252, 112582.	4.1	9
157	Troponins and natriuretic peptides to detect cardiotoxicity: useful biomarkers or paradise lost?. <i>European Journal of Heart Failure</i> , 2020, 22, 362-365.	7.1	2
158	Bevacizumab as a monoclonal antibody inhibits mitochondrial complex II in isolated rat heart mitochondria: ameliorative effect of ellagic acid. <i>Drug and Chemical Toxicology</i> , 2020, , 1-8.	2.3	13
159	Hospitalization after Adolescent and Young Adult (AYA) Cancer: A Population-Based Study in Utah. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 336-342.	2.5	4
160	Cardiotoxicity of Anthracyclines. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 26.	2.4	212
161	Multicomponent Compression Bandaging Combined with Diuretic Therapy of Anasarca Secondary to Palliative Chemotherapy: A Case Report. <i>Journal of Palliative Medicine</i> , 2021, 24, 144-147.	1.1	1
162	All-Cause and Cardiovascular Disease Mortality Among Breast Cancer Survivors in CLUE II, a Long-Standing Community-Based Cohort. <i>Journal of the National Cancer Institute</i> , 2021, 113, 137-145.	6.3	51
163	RIP1/RIP3/MLKL-mediated necroptosis contributes to vinblastine-induced myocardial damage. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 1233-1243.	3.1	20
164	Improving cardiotoxicity prediction in cancer treatment: integration of conventional circulating biomarkers and novel exploratory tools. <i>Archives of Toxicology</i> , 2021, 95, 791-805.	4.2	4
165	Treatment Limitation Decisions in Critically Ill Patients With a Malignancy on the Intensive Care Unit. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 42-50.	2.8	1
166	Acquired and modifiable cardiovascular risk factors in patients treated for cancer. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 846-853.	2.1	4
167	Identification of Clinical and Laboratory Variables Associated with Cardiotoxicity Events Due to Doxorubicin in Breast Cancer Patients: A 1-Year Follow-Up Study. <i>Cardiovascular Toxicology</i> , 2021, 21, 106-114.	2.7	7
168	Multienzyme nanoassemblies: from rational design to biomedical applications. <i>Biomaterials Science</i> , 2021, 9, 7323-7342.	5.4	7
169	Dexrazoxane ameliorates radiation-induced heart disease in a rat model. <i>Aging</i> , 2021, 13, 3699-3711.	3.1	9

#	ARTICLE	IF	CITATIONS
170	Exercise to Prevent Anthracycline-Based Cardiotoxicity (EXACT): A Feasibility Study. Translational Journal of the American College of Sports Medicine, 2021, 6, 1-11.	0.6	1
171	Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 341-348.	2.0	17
172	Medication Induced Cardiotoxicity and Skin Reactions. , 2021, , 341-390.		0
173	Zebrafish Models of Cancer Therapy-Induced Cardiovascular Toxicity. Journal of Cardiovascular Development and Disease, 2021, 8, 8.	1.6	5
174	Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy. Current Cardiology Reports, 2021, 23, 16.	2.9	12
175	Onco-Critical Care. , 2021, , 439-457.		0
176	Preventive Cardio-Oncology: Cardiovascular Disease Prevention in Cancer Patients and Survivors. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.9	5
177	Review of the Efficacy and Mechanisms of Traditional Chinese Medicines as a Therapeutic Option for Ionizing Radiation Induced Damage. Frontiers in Pharmacology, 2021, 12, 617559.	3.5	5
178	Attenuating Treatment-Related Cardiotoxicity in Women Recently Diagnosed With Breast Cancer via a Tailored Therapeutic Exercise Program: Protocol of the ATOPE Trial. Physical Therapy, 2021, 101, .	2.4	8
179	Prescribing Exercise in Early-Stage Breast Cancer During Chemotherapy: A Simple Periodized Approach to Align With the Cyclic Phases of Chemotherapy. Journal of Strength and Conditioning Research, 2022, 36, 2934-2941.	2.1	4
180	Sunitinib and Imatinib Display Differential Cardiotoxicity in Adult Rat Cardiac Fibroblasts That Involves a Role for Calcium/Calmodulin Dependent Protein Kinase II. Frontiers in Cardiovascular Medicine, 2020, 7, 630480.	2.4	11
181	Structural Transcatheter Cardiac Interventions in the Cardio-Oncology Population. Current Treatment Options in Cardiovascular Medicine, 2021, 23, 1.	0.9	2
182	Current status of treatment of cancer-associated venous thromboembolism. Thrombosis Journal, 2021, 19, 21.	2.1	23
183	Cardiovascular complications in patients with cancer: focus on anthracycline-induced cardiotoxicity. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2583.	1.4	1
184	Subtle cardiac dysfunction in lymphoma patients receiving low to moderate dose chemotherapy. Scientific Reports, 2021, 11, 7100.	3.3	4
185	Oncology professionals' perspectives towards cardiac surveillance in breast cancer patients with high cardiotoxicity risk: A qualitative study. PLoS ONE, 2021, 16, e0249067.	2.5	7
186	Early doxorubicin cardiotoxicity in Malawian children admitted to Queen Elizabeth Central Hospital, Malawi. Pediatric Blood and Cancer, 2021, 68, e29003.	1.5	2
187	Ischaemic and bleeding risk in cancer patients undergoing PCI: another brick in the wall. European Heart Journal, 2021, 42, 1035-1037.	2.2	5

#	ARTICLE	IF	CITATIONS
189	Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1647.	2.4	13
190	Therapeutic Potential of Hispidin—Fungal and Plant Polyketide. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 323.	3.5	18
191	Sodium—Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK—mTOR Signaling Pathway—Mediated Autophagy. <i>Frontiers in Pharmacology</i> , 2021, 12, 664181.	3.5	46
192	Telomerase therapy attenuates cardiotoxic effects of doxorubicin. <i>Molecular Therapy</i> , 2021, 29, 1395-1410.	8.2	31
193	GDF15 Promotes Cardiac Fibrosis and Proliferation of Cardiac Fibroblasts via the MAPK/ERK1/2 Pathway after Irradiation in Rats. <i>Radiation Research</i> , 2021, 196, 183-191.	1.5	10
194	Preliminary pre-clinical studies on the side effects of breast cancer treatment. <i>International Journal of Radiation Biology</i> , 2021, 97, 877-887.	1.8	8
195	Role of cardiovascular magnetic resonance in early detection and treatment of cardiac dysfunction in oncology patients. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 3003-3017.	1.5	4
196	MicroRNA-Responsive DNA-Programmed Nanomedicine with Controllability of Cascaded Events for Cancer Therapy Enhancement. <i>ACS Macro Letters</i> , 2021, 10, 654-661.	4.8	1
197	Personality Traits and Cardiotoxicity Arising From Cancer Treatments: An Hypothesized Relationship. <i>Frontiers in Psychology</i> , 2021, 12, 546636.	2.1	0
198	Cardiotoxicity and Cardiac Monitoring Among Anthracycline-Treated Cancer Patients: A Retrospective Cohort Study. <i>Cancer Management and Research</i> , 2021, Volume 13, 5149-5159.	1.9	5
199	The potential protective effects of malacca (<i>Phyllanthus emblica</i> L.) extract against doxorubicin-induced cardiotoxicity in male Wistar rats. <i>Jurnal Natural</i> , 2021, 21, 81-88.	0.3	0
200	Assessment of mortality and performance status in critically ill cancer patients: A retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0252771.	2.5	7
201	Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 690533.	2.4	4
202	Predicting Survival for Patients with Malignant Pleural Effusion: Development of the CONCH Prognostic Model. <i>Cancer Management and Research</i> , 2021, Volume 13, 4699-4707.	1.9	5
203	Recent Progress in Environmental Toxins-Induced Cardiotoxicity and Protective Potential of Natural Products. <i>Frontiers in Pharmacology</i> , 2021, 12, 699193.	3.5	8
204	Subclinical cardiac damage in cancer patients before chemotherapy. <i>Heart Failure Reviews</i> , 2022, 27, 1091-1104.	3.9	9
206	Quality of life in breast cancer patients with cancer treatment-related cardiac dysfunction: a qualitative study. <i>European Journal of Cardiovascular Nursing</i> , 2022, 21, 235-242.	0.9	6
208	All for one, though not one for all: team players in normal tissue radiobiology. <i>International Journal of Radiation Biology</i> , 2022, 98, 346-366.	1.8	2

#	ARTICLE	IF	CITATIONS
209	Shenmai injection improves doxorubicin cardiotoxicity via miR-30a/Beclin 1. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111582.	5.6	14
210	The Growing Impact of Cardiovascular Oncology: Epidemiology and Pathophysiology. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 899-906.	2.7	6
211	Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111708.	5.6	296
212	New progress in elucidating the relationship between cancer therapy and cardiovascular toxicity. <i>BioScience Trends</i> , 2021, 15, 211-218.	3.4	5
213	Dantrolene Prevents the Lymphostasis Caused by Doxorubicin in the Rat Mesenteric Circulation. <i>Frontiers in Pharmacology</i> , 2021, 12, 727526.	3.5	7
214	Rational, Design and Preliminary Results of a Cohort Study on Breast and Colorectal Cancer to Develop a Risk Assessment Model to Predict Future Cardiovascular Events. “Cardio Vascular Events in Breast and Colorectal Cancers (CIBC) Study” Current Problems in Cardiology, 2022, 47, 100958.	2.4	3
215	Analysis of lncRNA-miRNA-mRNA expression pattern in heart tissue after total body radiation in a mouse model. <i>Journal of Translational Medicine</i> , 2021, 19, 336.	4.4	20
216	Cardiac complications associated with hematopoietic stem-cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2637-2643.	2.4	11
217	A Polyphenol-Rich Extract of Olive Mill Wastewater Enhances Cancer Chemotherapy Effects, While Mitigating Cardiac Toxicity. <i>Frontiers in Pharmacology</i> , 2021, 12, 694762.	3.5	13
218	Thirty-Day Readmission Rates after Takotsubo Syndrome with or without Malignancy: A Nationwide Readmissions Database Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3701.	2.4	2
219	Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?. <i>Journal of Clinical Oncology</i> , 2021, 39, 3541-3545.	1.6	6
220	Cardiotoxicity Associated with Chemotherapy Used in Gastrointestinal Tumours. <i>Medicina (Lithuania)</i> , 2021, 57, 806.	2.0	4
221	Late excess mortality in essential thrombocythemia: a population-based study in the Netherlands, 2001-2018. <i>Leukemia</i> , 2021, , .	7.2	2
222	The Importance of Multidisciplinary Cardio-Oncology Team in the Breast Cancer Treatment with Anthracyclines. <i>Medicina Interna (Bucharest, Romania)</i> , 2021, 18, 67-75.	0.0	0
223	Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy. <i>Seminars in Cancer Biology</i> , 2022, 86, 929-942.	9.6	14
225	Risk Factors for Anthracycline-Induced Cardiotoxicity. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 736854.	2.4	28
226	Advances in Cardiotoxicity Induced by Altered Mitochondrial Dynamics and Mitophagy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 739095.	2.4	11
227	Cardiovascular mortality among cancer survivors who developed breast cancer as a second primary malignancy. <i>British Journal of Cancer</i> , 2021, 125, 1450-1458.	6.4	1

#	ARTICLE	IF	CITATIONS
228	Nicorandil Ameliorates Doxorubicin-Induced Cardiotoxicity in Rats, as Evaluated by 7ÂT Cardiovascular Magnetic Resonance Imaging. Cardiovascular Drugs and Therapy, 2023, 37, 39-51.	2.6	4
229	Genomic risk prediction of coronary artery disease in women with breast cancer: a prospective cohort study. Breast Cancer Research, 2021, 23, 94.	5.0	4
230	Role of acetylation in doxorubicin-induced cardiotoxicity. Redox Biology, 2021, 46, 102089.	9.0	59
231	A quantitative systems pharmacology approach to predict the safeâ€equivalent dose of doxorubicin in patients with cardiovascular comorbidity. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1512-1524.	2.5	5
232	Small-molecule fluorescence-based probes for interrogating major organ diseases. Chemical Society Reviews, 2021, 50, 9391-9429.	38.1	176
233	Association of Cancer With Outcomes in Patients Hospitalized for Heart Failure. Circulation Journal, 2020, 84, 1771-1778.	1.6	14
234	Long-Term Radiotherapy-Induced Cardiac Complications: A Case Report. American Journal of Case Reports, 2019, 20, 1182-1188.	0.8	7
235	Therapy-induced cardiotoxicity in breast cancer patients: a well-known yet unresolved problem. Discoveries, 2019, 7, e89.	2.3	17
237	First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapy. Meditsinskiy Sovet, 2019, , 42-48.	0.5	4
238	Antitumour Drug Induced Cardiovascular Toxicity and Current Tumour Treatment Methods. KreativnaÂ HirurgiÂ I OnkologiÂ, 2020, 9, 285-292.	0.3	3
239	Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I. Systemic Hypertension, 2017, 14, 6-20.	0.6	8
240	AblaÃ§Ã£o por Cateter sem Uso de Raios X para Tratamento de FibrilaÃ§Ã£o Atrial e Arritmias Atriais. Arquivos Brasileiros De Cardiologia, 2020, 114, 1027-1028.	0.8	4
241	Age-Dependent Increased Odds of Cardiovascular Risk Factors in Cancer Survivors: Canadian Longitudinal Study on Aging Cohort. Current Oncology, 2020, 27, 368-376.	2.2	4
242	Incidence of long-term cardiotoxicity and evolution of the systolic function in patients with breast cancer treated with anthracyclines. Cardiology Journal, 2022, 29, 228-234.	1.2	8
243	Successful Heart Transplant in a Childhood Cancer Survivor With Chemoradiotherapy-Induced Cardiomyopathy. Experimental and Clinical Transplantation, 2020, 18, 533-535.	0.5	1
244	Severe Cardiac Toxicity Induced by Cancer Therapies Requiring Intensive Care Unit Admission. Frontiers in Cardiovascular Medicine, 2021, 8, 713694.	2.4	10
245	Do diabetic complications influence cancer-related events in people with type 2 diabetes? A cohort approach. Diabetes and Metabolism, 2021, 48, 101289.	2.9	0
246	Cardiotoxicity of Antineoplastic Therapies and Applications of Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Cells, 2021, 10, 2823.	4.1	7

#	ARTICLE	IF	CITATIONS
267	Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers. Current Heart Failure Reports, 2021, 18, 362-377.	3.3	4
268	Personomics – an innovative tool of precision medicine and its role in the individualized treatment of patients with breast cancer. Asia-Pacific Journal of Oncology, 2020, , 1-8.	0.1	0
269	Cardiotoxicity After Childhood Cancer Treatment. , 2021, , 3-15.		0
270	Preventing cancer therapy-related heart failure: the need for novel studies. Journal of Cardiovascular Medicine, 2021, 22, 459-468.	1.5	4
271	Cardiovascular and Cancer Risk: The Role of Cardio-oncology. Journal of the Advanced Practitioner in Oncology, 2018, 9, 160-176.	0.4	15
272	Cardiotoxicity of chemotherapy and targeted agents. American Journal of Cancer Research, 2021, 11, 1132-1147.	1.4	3
273	Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Patients With Breast Cancer: Protocol for a Multi-Institutional Prospective Study. JMIR Research Protocols, 2022, 11, e31887.	1.0	3
274	Advances in Biomarkers for Detecting Early Cancer Treatment-Related Cardiac Dysfunction. Frontiers in Cardiovascular Medicine, 2021, 8, 753313.	2.4	19
275	Anthracycline-induced cardiotoxicity in women without cardiovascular diseases: molecular and genetic predictors. Acta Cardiologica, 2022, 77, 805-814.	0.9	4
276	Optimal authoritative risk assessment score of Cancer-associated venous thromboembolism for hospitalized medical patients with lung Cancer. Thrombosis Journal, 2021, 19, 95.	2.1	7
277	Complications associated with oncological therapy - how to minimize?. Journal of Education, Health and Sport, 2020, 10, 319-331.	0.1	0
278	Can ACEI/ARB prevent the cardiotoxicity caused by chemotherapy in early-stage breast cancer? – a meta-analysis of randomized controlled trials. Translational Cancer Research, 2020, 9, 7034-7043.	1.0	5
279	CARDIOTOXICITY RISK PREDICTION IN BREAST CANCER PATIENTS. Problemy Radiatsiinoi Medytsyny Ta Radiobiologii, 2021, 26, 498-512.	0.3	6
280	Evaluation of Diastolic Heart Function Using Echocardiography and Pulse Wave Analysis in Patients After Anthracycline Therapy. , 2021, , .		2
281	Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity. Drug Safety, 2022, 45, 101-126.	3.2	6
282	QTc prolongation during levofloxacin and triazole combination chemoprophylaxis: Prevalence and predisposing risk factors in a cohort of hematopoietic cell transplantation recipients. Journal of Oncology Pharmacy Practice, 2023, 29, 534-542.	0.9	0
283	Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics – Chinese Chemical Letters, 2022, , .	9.0	3
284	Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity. Frontiers in Cardiovascular Medicine, 2021, 8, 805735.	2.4	13

#	ARTICLE	IF	CITATIONS
285	Risk of Cardiovascular Toxicity According to Tumor Laterality Among Older Patients With Early Stage Non-small Cell Lung Cancer Treated With Radiation Therapy. <i>Chest</i> , 2022, 161, 1666-1674.	0.8	2
286	Injectable and pH-responsive self-assembled peptide hydrogel for promoted tumor cell uptake and enhanced cancer chemotherapy. <i>Biomaterials Science</i> , 2022, 10, 854-862.	5.4	31
287	Combinatorial effect of thymoquinone with chemo agents for tumor therapy. <i>Phytomedicine</i> , 2022, 98, 153936.	5.3	6
288	Right Ventricular Ejection Fraction Assessed by Three-Dimensional Echocardiography Is Associated with Long-Term Adverse Clinical Cardiac Events in Patients with Anthracycline-Induced Cardiotoxicity. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 600-608.e3.	2.8	5
289	Inequity in Cardio-Oncology: Identifying Disparities in Cardiotoxicity and Links to Cardiac and Cancer Outcomes. <i>Journal of the American Heart Association</i> , 2021, 10, e023852.	3.7	38
290	Long-Term Cardiac Damage Associated With Abdominal Irradiation in Mice. <i>Frontiers in Pharmacology</i> , 2022, 13, 850735.	3.5	2
291	Successful Management of Osimertinib-Induced Heart Failure. <i>Medicina (Lithuania)</i> , 2022, 58, 312.	2.0	3
292	A first approach to identifying cardiotoxic effects of breast cancer chemotherapeutic treatment in Kazakhstan. <i>Journal of Clinical Medicine of Kazakhstan</i> , 2022, 19, 28-35.	0.3	2
294	Long-Term Survival and Causes of Death After Diagnoses of Common Cancers in 3 Cohorts of US Health Professionals. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	2.9	7
295	Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 829553.	2.4	11
296	Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 727487.	2.4	18
297	Oscillometric evaluation of the effects of cardiotoxic chemotherapeutic agents on vascular stiffness. <i>Blood Pressure Monitoring</i> , 2022, Publish Ahead of Print, .	0.8	0
298	Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022). <i>Eurasian Heart Journal</i> , 2022, , 6-79.	0.8	6
299	How to Improve SBRT Outcomes in NSCLC: From Pre-Clinical Modeling to Successful Clinical Translation. <i>Cancers</i> , 2022, 14, 1705.	3.7	4
300	Immunomodulatory Treatment Strategies Targeting B Cells for Heart Failure. <i>Frontiers in Pharmacology</i> , 2022, 13, 854592.	3.5	3
301	Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy. <i>Journal of Investigative Medicine</i> , 2022, 70, 1352-1357.	1.6	3
302	Choline Protects the Heart from Doxorubicin-Induced Cardiotoxicity through Vagal Activation and Nrf2/HO-1 Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-22.	4.0	8
303	Research on rare earth doped mesoporous bioactive glass nanospheres. â.... Similarity of in vitro biological effects. <i>Journal of Non-Crystalline Solids</i> , 2022, 587, 121586.	3.1	8

#	ARTICLE	IF	CITATIONS
304	Racial disparities in mortality outcomes among women diagnosed with breast cancer in Maryland: Impact of cardiovascular disease and clinical characteristics. <i>Cancer</i> , 2022, 128, 727-736.	4.1	9
306	Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile. <i>Life</i> , 2022, 12, 48.	2.4	49
307	Cardiovascular Safety Assessment in Cancer Drug Development. <i>Journal of the American Heart Association</i> , 2021, 10, e024033.	3.7	5
308	Chemotherapy-Induced Arrhythmias. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 80, 531-539.	1.9	3
309	Established Tumour Biomarkers Predict Cardiovascular Events and Mortality in the General Population. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 753885.	2.4	10
311	Multimodality imaging in the assessment of bone marrow-derived mesenchymal stem cell therapy for doxorubicin-induced cardiomyopathy.. <i>American Journal of Cancer Research</i> , 2022, 12, 574-584.	1.4	0
312	Opportunities and Challenges in Cardio-Oncology: A Bibliometric Analysis From 2010 to 2022. <i>Current Problems in Cardiology</i> , 2023, 48, 101227.	2.4	12
313	Gasdermin D mediates doxorubicin-induced cardiomyocyte pyroptosis and cardiotoxicity via directly binding to doxorubicin and changes in mitochondrial damage. <i>Translational Research</i> , 2022, 248, 36-50.	5.0	25
314	Mechanical property evaluation of the right ventricular myocardium in cancer patients with chemotherapy by echocardiography: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2022, 11, 1122-1140.	1.0	1
315	Treatment-Related Coronary Disorders of Fluoropyrimidine Administration: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2022, 13, .	3.5	2
316	Practical Approaches to Build and Sustain a Cardio-Oncology Clinic. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 158.	1.6	2
317	Cancer-Associated Deep Vein Thrombosis: Insights from Randomized Trials and Real-Life Practice. <i>Flebologiya</i> , 2022, 16, 156.	1.0	1
318	Factors associated with the recovery of chemotherapy induced cardiomyopathy in HER2 overexpressing breast cancer. <i>Medical Science and Discovery</i> , 2022, 9, 283-287.	0.1	0
319	A Systematic Review of Nonclinical Studies on the Effect of Curcumin in Chemotherapy- induced Cardiotoxicity. <i>Current Pharmaceutical Design</i> , 2022, 28, 1843-1853.	1.9	4
320	Time for Paying Attention to Fluoropyrimidine-Associated Cardiotoxicity: A Meta-Analysis for Epidemiology Based on 60537 Subjects. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
321	Associations between Normal Organs and Tumor Burden in Patients Imaged with Fibroblast Activation Protein Inhibitor-Directed Positron Emission Tomography. <i>Cancers</i> , 2022, 14, 2609.	3.7	8
322	Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms. <i>Thrombosis Research</i> , 2022, 213, S95-S102.	1.7	9
323	Hypertensive events after the initiation of contemporary cancer therapies for breast cancer control. <i>Cancer Medicine</i> , 0, , .	2.8	2

#	ARTICLE	IF	CITATIONS
324	Venetoclax Induces Cardiotoxicity through Modulation of Oxidative-Stress-Mediated Cardiac Inflammation and Apoptosis via NF- κ B and BCL-2 Pathway. International Journal of Molecular Sciences, 2022, 23, 6260.	4.1	4
325	Biomarker Determinants of Early Anthracycline-Induced Left Ventricular Dysfunction in Breast Cancer: A Systematic Review and Meta-Analysis. Molecular Diagnosis and Therapy, 2022, 26, 369-382.	3.8	5
326	A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab. Current Oncology, 2022, 29, 4224-4234.	2.2	5
327	In situ Injection of pH- and Temperature-Sensitive Nanomaterials Increases Chemo-Photothermal Efficacy by Alleviating the Tumor Immunosuppressive Microenvironment. International Journal of Nanomedicine, 0, Volume 17, 2661-2678.	6.7	3
328	Relevance of Ferroptosis to Cardiotoxicity Caused by Anthracyclines: Mechanisms to Target Treatments. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	9
329	Cardiac-Related Lesions in Newly Diagnosed Patients With Acute Leukemia: A Chinese Population-Based Real-World Study. Frontiers in Medicine, 0, 9, .	2.6	1
330	Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies. JACC: CardioOncology, 2022, 4, 238-253.	4.0	10
331	Myocardial Dysfunction in Patients with Cancer. Heart Failure Clinics, 2022, 18, 361-374.	2.1	1
332	Modeling Susceptibility to Cardiotoxicity in Cancer Therapy Using Human iPSC-Derived Cardiac Cells and Systems Biology. Heart Failure Clinics, 2022, 18, 335-347.	2.1	1
333	Critical insights into cardiotoxicity of anthracyclines. , 2022, , 103-112.		0
334	<scp>AGS</scp> and <scp>NIA</scp> bench-to bedside conference summary: Cancer and cardiovascular disease. Journal of the American Geriatrics Society, 2022, 70, 2764-2774.	2.6	4
335	The combination of hydroxychloroquine and 2-deoxyglucose enhances apoptosis in breast cancer cells by blocking protective autophagy and sustaining endoplasmic reticulum stress. Cell Death Discovery, 2022, 8, .	4.7	15
336	Cardio-oncology: Understanding the different mechanisms of cardiovascular toxicity. Revista Portuguesa De Cardiologia, 2022, 41, 587-597.	0.5	1
337	Cancer Epidemiology, Prevention, and Survivorship. , 2023, , 3-14.		1
338	Insights on the molecular targets of cardiotoxicity induced by anticancer drugs: A systematic review based on proteomic findings. Metabolism: Clinical and Experimental, 2022, 134, 155250.	3.4	12
339	Trastuzumab-induced cardiotoxicity in early breast cancer over a 10-year period in Uruguay. Medicine (United States), 2022, 101, e29927.	1.0	2
340	Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase. Frontiers in Oncology, 0, 12, .	2.8	10
341	Breast Cancer and the Cardiovascular Disease: A Narrative Review. Cureus, 2022, , .	0.5	7

#	ARTICLE	IF	CITATIONS
342	Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies. Pharmaceuticals, 2022, 15, 1007.	3.8	3
343	Preventive use of beta-blockers for anthracycline-induced cardiotoxicity: A network meta-analysis. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	5
344	Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-10.	4.0	3
345	Cardiac Rehabilitation Improves Fitness in Patients With Subclinical Markers of Cardiotoxicity While Receiving Chemotherapy. Journal of Cardiopulmonary Rehabilitation and Prevention, 2023, 43, 129-134.	2.1	8
346	Current Status and Trends of Research on Anthracycline-Induced Cardiotoxicity from 2002 to 2021: A Twenty-Year Bibliometric and Visualization Analysis. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-21.	4.0	5
347	Doxorubicin-Induced Cardiotoxicity May Be Alleviated by Bone Marrow Mesenchymal Stem Cell-Derived Exosomal lncRNA via Inhibiting Inflammation. Journal of Inflammation Research, 0, Volume 15, 4467-4486.	3.5	4
348	Risk factors associated with cardiovascular mortality among gastric cancer patients: a population-based analysis. Japanese Journal of Clinical Oncology, 2022, 52, 1365-1374.	1.3	2
349	Non-coding RNAs in cancer therapy-induced cardiotoxicity: Mechanisms, biomarkers, and treatments. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	4
350	Cardiotoxicity among socioeconomically marginalized breast cancer patients. Breast Cancer Research and Treatment, 0, , .	2.5	0
351	Noninvasive Stereotactic Radiation for Refractory Ventricular Tachycardia After Failure of Cardiac Sympathetic Denervation. JACC: Case Reports, 2022, 4, 1189-1194.	0.6	1
352	Clonal hematopoiesis, somatic mosaicism, and age-associated disease. Physiological Reviews, 2023, 103, 649-716.	28.8	21
353	Chronic Oxidative Stress as a Marker of Long-term Radiation-Induced Cardiovascular Outcomes in Breast Cancer. Journal of Cardiovascular Translational Research, 2023, 16, 403-413.	2.4	2
354	Fucoidan Protects against Doxorubicin-Induced Cardiotoxicity by Reducing Oxidative Stress and Preventing Mitochondrial Function Injury. International Journal of Molecular Sciences, 2022, 23, 10685.	4.1	8
355	<scp>CaMKII</scp> orchestrates endoplasmic reticulum stress and apoptosis in doxorubicin-induced cardiotoxicity by regulating the <scp>IRE1</scp> pathway. Journal of Cellular and Molecular Medicine, 2022, 26, 5303-5314.	3.6	7
356	Role of non-cardiomyocytes in anticancer drug-induced cardiotoxicity: A systematic review. IScience, 2022, 25, 105283.	4.1	5
357	Echocardiographic strategy for early detection of cardiotoxicity of doxorubicin: a prospective observational study. Cardio-Oncology, 2022, 8, .	1.7	1
358	Cardio-Oncology in Childhood: State of the Art. Current Oncology Reports, 2022, 24, 1765-1777.	4.0	1
359	Mitochondrial Dynamin-Related Protein Drp1: a New Player in Cardio-oncology. Current Oncology Reports, 2022, 24, 1751-1763.	4.0	6

#	ARTICLE	IF	CITATIONS
360	Cardiac biomarkers in the field of cardio-oncology. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, e1-e2.	1.0	1
361	Cardiovascular Complications in Hematopoietic Stem Cell Transplanted Patients. <i>Journal of Personalized Medicine</i> , 2022, 12, 1797.	2.5	5
362	Maternal Cardiovascular Outcomes of Pregnancy in Childhood, Adolescent, and Young Adult Cancer Survivors. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 373.	1.6	2
363	High cardiovascular disease mortality after penile squamous cell carcinomas diagnosis: Results from the United States SEER population, 2005-2016. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
364	Protecting the Heart in Cancer Patients: The Role of Cardio-Oncology. <i>EMJ Cardiology</i> , 0, , 47-52.	0.0	1
365	Cardioprotective potential of vanillic acid. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2023, 50, 193-204.	1.9	9
366	Role and molecular mechanism of traditional Chinese medicine in preventing cardiotoxicity associated with chemoradiotherapy. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	4
367	Preliminary results of reduced myocardial blood flow in the subacute phase after radiation therapy for thoracic esophageal cancer: A quantitative analysis with stress dynamic myocardial computed tomography perfusion imaging. <i>Radiotherapy and Oncology</i> , 2022, , .	0.6	0
368	Development and Psychometric Validation of the Nursing Self-Efficacy Scale for Managing Cancer Treatment-Induced Cardiotoxicity: An Exploratory Mixed-Method Study. <i>Seminars in Oncology Nursing</i> , 2022, , 151367.	1.5	2
369	Early myocardial oedema can predict subsequent cardiomyopathy in high-dose anthracycline therapy. <i>ESC Heart Failure</i> , 2023, 10, 616-627.	3.1	2
370	Global longitudinal strain: an early marker for cardiotoxicity in patients treated for breast cancer. <i>Netherlands Heart Journal</i> , 2023, 31, 103-108.	0.8	3
371	Cardiooncology: current status of the issue, interdisciplinary interaction. <i>Sarkomy Kosteji, Mâçgkih Tkanej I Opuholi KoÅ¾i</i> , 2022, 14, 22-25.	0.2	0
373	An efficient human stem cells derived cardiotoxicity testing platform for testing oncotherapeutic analogues of quercetin and cinnamic acid. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
374	CARDIOTOXICITY IN BREAST CANCER PATIENTS: RELATIONSHIP OF HS/TROPONIN T CHANGES AND HEART FUNCTION IN CANCER TREATMENT. <i>Problemy Radiatsiinoi Medytsyny Ta Radiobiologii</i> , 2022, 27, 440-454.	0.3	2
375	Identification of novel biomarkers involved in doxorubicin-induced acute and chronic cardiotoxicity, respectively, by integrated bioinformatics. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	0
376	Safety and efficacy of transcatheter edge-to-edge repair (TEER) in patients with history of cancer. <i>IJC Heart and Vasculature</i> , 2023, 44, 101165.	1.1	1
377	Ethanollic leaf extract of <i>Datura stramonium</i> attenuates methotrexate-induced biochemical alterations in Wistar Albino rats. , 2023, 2, .		2
378	Incidence and risk factors of cardiovascular mortality in patients with gastrointestinal adenocarcinoma. <i>PLoS ONE</i> , 2023, 18, e0262013.	2.5	1

#	ARTICLE	IF	CITATIONS
379	Correlation of Mean Heart Dose and Cardiac Biomarkers with Electrocardiographic Changes in Patients Receiving Thoracic Radiation Therapy. <i>Radiation Research</i> , 2023, , .	1.5	0
380	In-hospital and one-year outcomes in cancer patients receiving percutaneous coronary intervention for acute myocardial infarction: A real-world study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	1
381	Unraveling Structural Alerts in Marketed Drugs for Improving Adverse Outcome Pathway Framework of Drug-Induced QT Prolongation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6771.	4.1	0
382	Patient Information Resources on Cardiovascular Health After Cancer Treatment: An Audit of Australian Resources. <i>JCO Global Oncology</i> , 2023, , .	1.8	4
383	Recruitment rates and strategies in exercise trials in cancer survivorship: a systematic review. <i>Journal of Cancer Survivorship</i> , 0, , .	2.9	8
384	Long-Term Atherosclerotic Cardiovascular Disease Risk in Patients With Cancer: A Population-Based Study. <i>Current Problems in Cardiology</i> , 2023, 48, 101693.	2.4	1
385	Influence of polycrystalline MoS2 nanoflowers on mouse breast cancer cell proliferation via molten salt sintering. <i>Arabian Journal of Chemistry</i> , 2023, 16, 104596.	4.9	0
386	Variability of cardiac troponin levels in normal subjects and in patients with cardiovascular diseases: analytical considerations and clinical relevance. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 1209-1229.	2.3	12
387	Berberine Alleviates Doxorubicin-Induced Myocardial Injury and Fibrosis by Eliminating Oxidative Stress and Mitochondrial Damage via Promoting Nrf-2 Pathway Activation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3257.	4.1	5
388	Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology. <i>Current Cardiology Reports</i> , 2023, 25, 133-146.	2.9	7
389	Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	1
390	The Cardiovascular Risks Associated with Aromatase Inhibitors, Tamoxifen, and GnRH Agonists in Women with Breast Cancer. <i>Current Atherosclerosis Reports</i> , 2023, 25, 145-154.	4.8	2
392	Case report: Complete atrio-ventricular block successfully reversed in newly diagnosed primary cardiac B-cell lymphoma. <i>Frontiers in Medicine</i> , 0, 10, .	2.6	1
393	Anthracycline cardiotoxicity: current methods of diagnosis and possible role of 18F-FDG PET/CT as a new biomarker. <i>Cardio-Oncology</i> , 2023, 9, .	1.7	4
394	RBL2 Regulates Cardiac Sensitivity to Anthracycline Chemotherapy. <i>JACC: CardioOncology</i> , 2023, 5, 360-373.	4.0	1
395	Redefining the Incidence and Profile of Fluoropyrimidine-Associated Cardiotoxicity in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Pharmaceuticals</i> , 2023, 16, 510.	3.8	0
397	Detection of right ventricular dysfunction by three “dimensional echocardiography and two -dimensional speckle tracking in breast cancer patients receiving anthracycline- based chemotherapy. <i>Cardio-Oncology</i> , 2023, 9, .	1.7	0
398	Effects of Traditional Chinese Medicine Injections for Anthracyclines-induced Cardiotoxicity: An Overview of Systematic Reviews and Meta-Analyses. <i>Integrative Cancer Therapies</i> , 2023, 22, 153473542311647.	2.0	1

#	ARTICLE	IF	CITATIONS
399	Chemotherapy and chemoembolization of patients with oncopathology as a risk factor for the development of myocardial dysfunction. Journal of Clinical Medicine of Kazakhstan, 2023, 20, 4-8.	0.3	0
400	Evaluation of the RDW Index (Red Cell Distribution Width) in Women with Breast Cancer Treated with Doxorubicin in a One-Year Follow-Up Study. Diagnostics, 2023, 13, 1552.	2.6	2
401	Current perspectives of cardio-oncology: Epidemiology, adverse effects, pre-treatment screening and prevention strategies. Cancer Medicine, 2023, 12, 14545-14555.	2.8	2
402	The impact of tumor characteristics on cardiovascular disease death in breast cancer patients with CT or RT: a population-based study. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
403	Cyclophosphamide enfeebls myocardial isometric contraction force via RIP1/RIP3/MLKL/TRPM7-mediated necroptosis. Biomedicine and Pharmacotherapy, 2023, 163, 114819.	5.6	3
404	Functional Capacity in Cardiotoxicity: Effects of Physical Exercise. , 2022, 2, 410-414.		0
405	Cardiac Molecular Remodeling by Anticancer Drugs: Doxorubicin Affects More Metabolism While Mitoxantrone Impacts More Autophagy in Adult CD-1 Male Mice. Biomolecules, 2023, 13, 921.	4.0	1
406	Interventional Cardio-Oncology: Unique Challenges and Considerations in a High-Risk Population. Current Treatment Options in Oncology, 2023, 24, 1071-1087.	3.0	1
407	Remote Monitoring of the QT Interval During Polychemotherapy. Kardiologiya, 2023, 63, 12-18.	0.7	0
408	Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review. Frontiers in Pharmacology, 0, 14, .	3.5	0
409	Pharmacological effects and mechanisms of paeonol on antitumor and prevention of side effects of cancer therapy. Frontiers in Pharmacology, 0, 14, .	3.5	2
410	Physical and functional evaluations in oncological patients elective to medium and large operations. Supportive Care in Cancer, 2023, 31, .	2.2	1
411	New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review. Cancers, 2023, 15, 3290.	3.7	2
412	Technological Advancement in the Synthesis and Application of Nanocatalysts. , 2023, , 191-214.		0
413	d-Limonene complexed with cyclodextrin attenuates cardiac arrhythmias in an experimental model of doxorubicin-induced cardiotoxicity: Possible involvement of calcium/calmodulin-dependent protein kinase type II. Toxicology and Applied Pharmacology, 2023, 474, 116609.	2.8	2
414	Cancer therapy-related cardiac dysfunction: the need for a better understanding. British Journal of Cardiac Nursing, 2023, 18, 1-4.	0.1	0
415	Anthracycline-Induced Cardiotoxicity: the Role of Genetic Predictors. Kardiologiya, 2023, 63, 22-28.	0.7	2
416	Early diagnostic value of high-sensitivity cardiac troponin T for cancer treatment-related cardiac dysfunction: a meta-analysis. ESC Heart Failure, 2023, 10, 2170-2182.	3.1	5

#	ARTICLE	IF	CITATIONS
417	Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer, 2023, 23, e380-e393.	2.4	8
418	Ultrasoundâ€Triggered Cascade Amplification of Nanotherapy. Advanced Materials, 2023, 35, .	21.0	6
419	A COVID-19 Diagnosis Like an Avalanche Triggers a Series of Adverse Events but Saves a Life in the End. Healthcare (Switzerland), 2023, 11, 1847.	2.0	0
420	Cancer Therapy-Related Cardiotoxicity: A Comprehensive Retrospective Analysis at Najran Cancer Center, Saudi Arabia. Cureus, 2023, , .	0.5	0
423	Nrf2: a dark horse in doxorubicin-induced cardiotoxicity. Cell Death Discovery, 2023, 9, .	4.7	8
424	Cardio-oncology: Shared Genetic, Metabolic, and Pharmacologic Mechanism. Current Cardiology Reports, 0, , .	2.9	0
426	Targeting mitochondrial dynamics proteins for the treatment of doxorubicin-induced cardiotoxicity. Frontiers in Molecular Biosciences, 0, 10, .	3.5	5
427	Protection against cancer therapy-induced cardiovascular injury by planed-derived polyphenols and nanomaterials. Environmental Research, 2023, 238, 116896.	7.5	0
428	Hyperhomocysteinaemia Promotes Doxorubicin-Induced Cardiotoxicity in Mice. Pharmaceuticals, 2023, 16, 1212.	3.8	1
429	Radiation-associated Arrhythmias: Putative Pathophysiological Mechanisms, Prevalence, Screening and Management Strategies. Arrhythmia and Electrophysiology Review, 0, 12, .	2.4	1
430	Role of RIPK3â€CaMKIIâ€mPTP signaling pathwayâ€mediated necroptosis in cardiovascular diseases (Review). International Journal of Molecular Medicine, 2023, 52, .	4.0	2
431	Value of Echocardiography and Cardiac Magnetic resonance in assessing left ventricular function in breast and gastric cancer patients after Anthracycline Chemotherapy. BMC Cardiovascular Disorders, 2023, 23, .	1.7	0
432	Abnormal Global Longitudinal Strain During Anthracycline Treatment Predicts Future Cardiotoxicity in Children. Pediatric Cardiology, 0, , .	1.3	0
433	Multimodal Imaging of Cancer Therapy-Related Cardiac Dysfunction in Breast Cancerâ€”A State-of-the-Art Review. Journal of Clinical Medicine, 2023, 12, 6295.	2.4	2
436	Antineoplastic drugs inducing cardiac and vascular toxicity â€“ An update. Vascular Pharmacology, 2023, 153, 107223.	2.1	2
437	Sympathetic neural overdrive and diminished exercise capacity in reduced ejection fraction heart failure related to anthracycline-based chemotherapy. American Journal of Physiology - Heart and Circulatory Physiology, 2023, 325, H1126-H1132.	3.2	0
438	Cardiotoxicity in breast cancer treatment: Causes and mitigation. Cancer Treatment and Research Communications, 2023, 37, 100760.	1.7	1
440	DICTrank: The largest reference list of 1318 human drugs ranked by risk of drug-induced cardiotoxicity using FDA labeling. Drug Discovery Today, 2023, 28, 103770.	6.4	2

#	ARTICLE	IF	CITATIONS
441	The Role of p90 Ribosomal S6 Kinase (RSK) in Tyrosine Kinase Inhibitor (TKI)-Induced Cardiotoxicity. Journal of Cardiovascular Translational Research, 0, , .	2.4	0
442	Overcoming right heart failure through successful treatment of cardiac dominant diffuse large B-cell lymphoma: a case report. Annals of Hematology, 0, , .	1.8	0
443	Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study. JCO Precision Oncology, 2023, , .	3.0	0
444	Emodin attenuates cardiomyocyte pyroptosis in doxorubicin-induced cardiotoxicity by directly binding to GSDMD. Phytomedicine, 2023, 121, 155105.	5.3	1
445	Đ’Đ»Đ,ŃĐ1/2Đ,Đµ Đ,ŃĐµĐ1/4Đ,ŃĐµŃĐ°Đ3/4Đ1 Đ±Đ3/4Đ»ĐµĐ·Đ1/2Đ, ŃĐµŃĐŃĐŃĐ° Đ1/2Đ° Đ3ĐµĐ1/2Đ3/4Đ1/4Đ1/2ŃĐŃĐŃĐ1Đ1/2ĐµŃĐ,Đ°Đ±Đ	0.7	0
446	Evaluation of 2,3-dihydroimidazo[2,1- <i>b</i>]oxazole and imidazo[2,1- <i>a</i>]oxazole derivatives as chemotherapeutic agents. Future Medicinal Chemistry, 0, , .	2.3	1
447	Recent Perspectives on Cardiovascular Toxicity Associated with Colorectal Cancer Drug Therapy. Pharmaceuticals, 2023, 16, 1441.	3.8	0
448	Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications. Biomedicine and Pharmacotherapy, 2023, 168, 115686.	5.6	3
449	Prognostic value of humoral markers in patients with anthracycline-related cardiac dysfunction. Bulletin of Siberian Medicine, 2023, 22, 25-35.	0.3	0
450	SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction. JACC: Heart Failure, 2024, 12, 67-78.	4.1	4
451	Doxorubicin-induced modulation of TGF-β2 signaling cascade in mouse fibroblasts: insights into cardiotoxicity mechanisms. Scientific Reports, 2023, 13, .	3.3	1
452	Cardiac electrical abnormalities in childhood acute lymphoblastic leukemia survivors: a systematic review. Cardio-Oncology, 2023, 9, .	1.7	1
453	Trilogy of drug repurposing for developing cancer and chemotherapy-induced heart failure co-therapy agent. Acta Pharmaceutica Sinica B, 2023, , .	12.0	0
454	Alkaloid-rich extract of Lannea egregia leaf protect against cardiomyopathy in streptozotocin-induced type 2 diabetic rats. Phytomedicine Plus, 2024, 4, 100513.	2.0	0
455	Bioinformatics and experimental studies jointly reveal that Sacubitril Valsartan improves myocardial oxidative stress and inflammation by regulating the MAPK signaling pathway to treat chemotherapy related cardiotoxicity. Biochemical and Biophysical Research Communications, 2024, 690, 149244.	2.1	0
456	mtADENet: A novel interpretable method integrating multiple types of network-based inference approaches for prediction of adverse drug events. Computers in Biology and Medicine, 2024, 168, 107831.	7.0	1
457	Cardiotoxicity of Agents Used in Patients With Breast Cancer. JCO Oncology Practice, 2024, 20, 38-46.	2.9	1
458	Developing Cardio-Oncology Programs in the New Era: Beyond Ventricular Dysfunction Due to Cancer Treatments. Cancers, 2023, 15, 5885.	3.7	0

#	ARTICLE	IF	CITATIONS
459	Anthracycline-induced cardiotoxicity: mechanisms, monitoring, and prevention. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	0
460	Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity. <i>Current Problems in Cardiology</i> , 2024, 49, 102350.	2.4	0
461	RISK SCORE MODEL FOR PREDICTING CARDIOTOXICITY IN BREAST CANCER: DIAGNOSTIC VALUE OF HIGH-SENSITIVITY CARDIAC TROPONIN T. <i>Problemy Radiatsiinoi Medytsyny Ta Radiobiologii</i> , 2023, 28, 454-467.	0.3	0
462	Effect of Intensive Blood Pressure Control on Cardiovascular Outcomes in Cancer Survivors. <i>Hypertension</i> , 2024, 81, 620-628.	2.7	0
463	Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 0, , .	3.0	0
464	Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies. <i>Blood Reviews</i> , 2023, , 101166.	5.7	0
466	New Concepts in Cardio-Oncology. <i>Cancer Treatment and Research</i> , 2023, , 303-341.	0.5	0
467	Psychometric Properties of the Turkish CardioToxicity Management Self-Efficacy Scale for Nurses. <i>Seminars in Oncology Nursing</i> , 2024, 40, 151573.	1.5	0
468	Improving measured health-related quality of life with outpatient high-dose methotrexate regimen among oncology patients with intracranial metastases: A systematic assessment. <i>Archives of Nursing Practice and Care</i> , 2023, 9, 008-014.	0.2	0
469	Cause-specific mortality in a population-level cohort of diffuse large B-cell lymphoma following chemotherapy in the early 21st century. <i>Annals of Hematology</i> , 2024, 103, 1675-1685.	1.8	0
470	Left ventricular mechanical dyssynchrony after chemotherapy in breast cancer patients with normal rest gated SPECT-MPI. <i>Annals of Nuclear Medicine</i> , 2024, 38, 272-277.	2.2	0
471	Characteristics and Outcomes of Cardiac Rehabilitation Patients With and Without Cancer: Insights From Western Sydney. <i>Heart Lung and Circulation</i> , 2024, , .	0.4	0
472	Development of a risk assessment model for cardiac injury in patients newly diagnosed with acute myeloid leukemia based on a multicenter, real-world analysis in China. <i>BMC Cancer</i> , 2024, 24, .	2.6	1
473	A comparative study of boost dose delivery techniques in breast cancer radiotherapy optimising efficacy and minimising toxicity. <i>Radiation Protection Dosimetry</i> , 2024, 200, 459-466.	0.8	0
474	Cardioprotection Using Doxorubicin: The Role of Dexrazoxane. , 0, , .		0
475	Cardiac Biomarkers. , 2023, , 295-306.		0
476	Review of Carrier-Free Self-Assembly of Anticancer Nanodrugs. <i>ACS Applied Nano Materials</i> , 2024, 7, 4564-4587.	5.0	0
477	An Integrated Network Pharmacology and RNA-seq Approach for Exploring the Protective Effect of Andrographolide in Doxorubicin-Induced Cardiotoxicity. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	2.6	0

#	ARTICLE	IF	CITATIONS
478	Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: aÂprospective cohort study. EClinicalMedicine, 2024, 69, 102504.	7.1	0
479	Guideline-directed medical therapy in chemotherapy-induced cardiotoxicity and heart failure: current perspectives and practices. Cardiology Plus, 2024, 9, 41-48.	0.7	0
480	Recent Advances in Artificial Intelligence and Cancer Treatment. , 2024, , .		0
481	Cardiovascular Toxicity of Antineoplastic Treatments in Hematological Diseases: Focus on Molecular Mechanisms to Improve Therapeutic Management. Journal of Clinical Medicine, 2024, 13, 1574.	2.4	0
482	Exploring the effects of calycosin on anthracycline-induced cardiotoxicity: a network pharmacology, molecular docking, and experimental study. Frontiers in Cardiovascular Medicine, 0, 11, .	2.4	0
483	Primary Prevention of Cardiovascular Disease in Women. Methodist DeBakey Cardiovascular Journal, 2024, 20, 94-106.	1.0	0
484	Cardiotoxic effects of common and emerging drugs: role of cannabinoid receptors. Clinical Science, 2024, 138, 413-434.	4.3	0
485	A review of chemotherapeutic drugs-induced arrhythmia and potential intervention with traditional Chinese medicines. Frontiers in Pharmacology, 0, 15, .	3.5	0